ROMA is a qualitative serum test that combines the results of HE4, CA 125, and menopausal status into a numerical score.
ROMA is used to assist in evaluating whether a pre-menopausal or post-menopausal woman with an ovarian adnexal mass has a high or low probability of finding malignancy on surgery. ROMA is for women who meet the following criteria:
- Over 18 years of age.
- Ovarian adnexal mass present for which surgery is planned, but referral is not yet made to an oncologist.
ROMA is not intended to be a screening or stand-alone diagnostic assay and therefore must be interpreted in conjunction with an independent clinical and radiological assessment.